CLINICAL_TRIALS
trial_result
· 2020-05-14
Clinical Trial Update: An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis [Phase 3]
Summary
Phase 3 trial update for guselkumab (CNTO 1959) in moderate to severe plaque psoriasis; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Janssen Pharmaceutical K.K. | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2020-05-14